Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.
about
Profiling immunity to HIV vaccines with systems biologyValidation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validationP. falciparum enhances HIV replication in an experimental malaria challenge systemA phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccineHigh proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088)Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function.Cryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy.Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells.Heterotypic humoral and cellular immune responses following Norwalk virus infection.Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)Equivalence of ELISpot assays demonstrated between major HIV network laboratoriesSpecificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesEnrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract.Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons.Quality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting.Early skewed distribution of total and HIV-specific CD8+ T-cell memory phenotypes during primary HIV infection is related to reduced antiviral activity and faster disease progressionThe External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assayThe Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells.Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials.Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal.Quality assurance of intracellular cytokine staining assays: analysis of multiple rounds of proficiency testing.Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancerA phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsImpact of blood processing variations on natural killer cell frequency, activation, chemokine receptor expression and function.Persistence of mucosal T-cell responses to herpes simplex virus type 2 in the female genital tractGuidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories.Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assaysPhase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: implications for immune cell biobanking.Stability and transport of cervical cytobrushes for isolation of mononuclear cells from the female genital tractHIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialAugmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection.Natural killer cell and T-cell subset distributions and activation influence susceptibility to perinatal HIV-1 infection.Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable.Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells.Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.
P2860
Q27010629-EF4EB41E-0007-45D9-BAC6-738B388551F6Q28075719-16CE4590-F5AA-43C8-A7E6-EE4F63740578Q28727971-6DFA11D5-A259-4095-A314-0B4FF7F23417Q28741673-40565452-6047-4156-AFAE-291AC9420EC8Q28744503-49BC070D-125A-4213-B1B4-9FF41B1BA5D4Q30373691-6A8B16C3-7533-4E64-BA7F-68393764DF18Q30426654-4414F2D6-EF10-43EB-8AF1-956E327EBC0BQ30432896-111C4D31-9888-493D-8868-4E7D2F8C0A73Q33551527-319E7928-7094-4A9C-A164-3AA50B3E1C91Q33601830-0CC7F32F-FD0E-4184-A4A1-1444DC99BFFBQ33614589-5DA02331-EE09-4FB6-980F-EBCA49FB8A78Q33737476-BA9642E1-19F8-4514-A872-38E03CEED33EQ33778327-9AE67AEC-58E1-4500-94E8-82CD2D1FEE4FQ33813145-8B02817F-2A9B-4554-A14C-1BB5875453A3Q33870372-5FB82B8F-0639-4FEB-A0ED-82E5BE699B2FQ33881052-46E3E0EC-BD63-442D-A932-338DE929773FQ33909178-D793A26C-575D-4233-9BC7-0B26E985EE9AQ34004816-65B2EEA9-2218-477B-BCA6-DB4C489F096CQ34066932-F4E57E7D-50AB-4ED8-BACA-8965F1586426Q34067001-DB72AEE6-E51A-4CBF-8EBC-EF01CDA17959Q34125277-C3867B77-9E9D-4FC9-8E21-C809CE10F507Q34225046-E47BD37E-2240-4EF2-8659-96F594967FF9Q34332340-27C18F53-B957-4C93-866C-F69E7DC208FDQ34414321-59889C8C-87D9-4F94-96A0-14AC54F784F5Q34537331-F1B84D1B-2B00-49ED-ABFA-17D9B2835760Q34593969-6B6870A3-B37F-4756-8B0F-377B77F4272BQ34634371-CDC0A03F-4207-4252-9238-B32C74ED6160Q34681733-35C69C30-E94F-4E34-B6D1-A366183270F1Q34718060-CD44E777-A42D-4438-AADB-DFF23F8EA1CBQ34743422-92E78F1E-BA81-43F1-BAC3-83C33FD83054Q34772727-A0BCA606-9A09-40DB-A196-010F61ED4235Q34776611-2E87B20E-EAA1-42AF-90DB-B468B48B1F65Q34837115-2087909E-D534-42E5-A407-98218F8404EDQ35140001-CDCB9C34-52D8-424A-8DD5-EE7E4C31706FQ35175897-3AD396AF-2E97-493C-8383-AF0F4B78BDF6Q35195360-B3D7D3E4-4298-4AE1-AA1C-C4E0BBB223D1Q35202180-72B7606A-51FB-4B4F-BB17-A1A135B0E6E0Q35234257-4269F1F7-5D8C-40C6-BA23-7DA219E1665BQ35531705-528BE4F1-7617-49FD-AC3E-3C55D3960B76Q35611969-D1091CF9-AEA9-4FAB-AAA4-A8481D152412
P2860
Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Defining blood processing para ...... ponses for HIV vaccine trials.
@ast
Defining blood processing para ...... ponses for HIV vaccine trials.
@en
type
label
Defining blood processing para ...... ponses for HIV vaccine trials.
@ast
Defining blood processing para ...... ponses for HIV vaccine trials.
@en
prefLabel
Defining blood processing para ...... ponses for HIV vaccine trials.
@ast
Defining blood processing para ...... ponses for HIV vaccine trials.
@en
P2093
P2860
P1476
Defining blood processing para ...... ponses for HIV vaccine trials.
@en
P2093
Abbe Rubin
Deborah Lee
Helen Horton
Jason Stucky
Marta Bull
Ya-Lin Chiu
P2860
P356
10.1016/J.JIM.2007.02.003
P577
2007-02-28T00:00:00Z